The modulation of PD-L1 induced by the oncogenic HBXIP for breast cancer growth
Fei-fei Xu,Hui-min Sun,Run-ping Fang,Lu Zhang,Hui Shi,Xue Wang,Xue-li Fu,Xian-meng Li,Xu-he Shi,Yue Wu,Kai Ye,Wei-ying Zhang,Li-hong Ye
DOI: https://doi.org/10.1038/s41401-021-00631-6
IF: 7.169
2021-04-06
Acta Pharmacologica Sinica
Abstract:Programmed death ligand-1 (PD-L1)/PD-1 checkpoint extensively serves as a central mediator of immunosuppression. A tumor-promoting role for abundant PD-L1 in several cancers is revealed. However, the importance of PD-L1 and how the PD-L1 expression is controlled in breast cancer remains obscure. Here, the mechanisms of controlling PD-L1 at the transcription and protein acetylation levels in promoting breast cancer growth are presented. Overexpressed PD-L1 accelerates breast cancer growth in vitro and in vivo. RNA-seq uncovers that PD-L1 can induce some target genes affecting many cellular processes, especially cancer development. In clinical breast cancer tissues and cells, PD-L1 and HBXIP are both increased, and their expressions are positively correlated. Mechanistic exploration identifies that HBXIP stimulates the transcription of PD-L1 through co-activating ETS2. Specifically, HBXIP induces PD-L1 acetylation at K270 site through interacting with acetyltransferase p300, leading to the stability of PD-L1 protein. Functionally, depletion of HBXIP attenuates PD-L1-accelerated breast tumor growth. Aspirin alleviates breast cancer via targeting PD-L1 and HBXIP. Collectively, the findings display new light into the mechanisms of controlling tumor PD-L1 and broaden the utility for PD-L1 as a target in breast cancer therapy.
pharmacology & pharmacy,chemistry, multidisciplinary